BioMarin Pharmaceuticals
BMRN
415 hedge funds and large institutions have $14B invested in BioMarin Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 56 funds opening new positions, 159 increasing their positions, 151 reducing their positions, and 57 closing their positions.
98.49% more ownership
Funds ownership: 0% → 98.49% (+98%)
5% more repeat investments, than reductions
Existing positions increased: 159 | Existing positions reduced: 151
2% less first-time investments, than exits
New positions opened: 56 | Existing positions closed: 57
5% less call options, than puts
Call options by funds: $90.6M | Put options by funds: $95.7M
2% less funds holding
Funds holding: 424 → 415 (-9)
10% less capital invested
Capital invested by funds: $15.6B → $14B (-$1.53B)
15% less funds holding in top 10
Funds holding in top 10: 13 → 11 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MNA
Manning & Napier Advisors
Fairport,
New York
|
+$162M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$84M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
+$78.1M |
| 4 |
Primecap Management
Pasadena,
California
|
+$66.9M |
| 5 |
HM
HealthCor Management
New York
|
+$66.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$120M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$102M |
| 3 |
Sands Capital Management
Arlington,
Virginia
|
-$72.3M |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
-$49.3M |
| 5 |
FAM
Fred Alger Management
New York
|
-$48.1M |
BMRN Hedge Fund Activity: Q4 2016 in Review
415 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q4 2016, worth a combined $14B — down 9.9% from $15.6B a quarter earlier.
Sellers outnumbered buyers: 57 funds closed out of BMRN and 56 opened new positions — a net loss of 1 holder — while 151 trimmed existing stakes and 159 added.
The largest buyer was Manning & Napier Advisors, adding an estimated $162M. The largest seller was T. Rowe Price Associates, cutting an estimated $120M.
- 415 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q4 2016, down from 424 in Q3 2016.
- Funds reported $14B of BioMarin Pharmaceuticals stock for Q4 2016, down 9.9% quarter-over-quarter.
- 56 funds opened new BioMarin Pharmaceuticals positions in Q4 2016 and 57 closed out, a net change of -1 holder.
- The largest BioMarin Pharmaceuticals buyer in Q4 2016 was Manning & Napier Advisors, an estimated $162M added.
- The largest BioMarin Pharmaceuticals seller in Q4 2016 was T. Rowe Price Associates, an estimated $120M sold.
Based on aggregated 13F filings for Q4 2016.